Abstract 146P
Background
This meta-analysis collected studies with propensity score matching analysis (PSM) or Randomized Controlled Trial(RCT) and focused on comparing the short-term and oncological outcomes of patients with HCC who underwent anatomic liver resection (AR) versus non-anatomic liver resection (NAR), to provide relatively high-level evidence of AR in treating patients with HCC in comparison with NAR.
Methods
A systematic literature search was performed using the PubMed, Embase, Cochrane Library and Web of Science to identify studies comparing AR with NAR by June 2019. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to evaluate the quality of the research included. The data were analyzed using Review Manager (Version 5.3). Dichotomous data were calculated by odds ratio (OR) and continuous data were calculated by weighed mean difference (WMD) with 95% confidence intervals (CI).
Results
A total of 11 studies (PSM=10; RCT=1) enrolling 2905 patients (AR = 1452; NAR=1453) with HCC were included in the present meta-analysis. For oncological outcomes, no significant differences were observed in disease-free survival (1 year: OR = 0.75, 95% CI:0.55∼1.03, P = 0.07; 3 year: OR = 0.85, 95% CI: 0.70∼1.03, P = 0.09; 5 year: OR = 0.87, 95% CI: 0.70∼1.10, P = 0.24) and overall survival (1 year: OR = 1.04, 95% CI:0.78∼1.38, P = 0.79; 3 year: OR = 0.88, 95% CI: 0.63∼1.23, P = 0.47; 5 year: OR = 0.82, 95% CI: 0.58∼1.17, P = 0.27) between the two groups. In addition, the pooled analysis suggested that no differences were found between the AR groups and NAR group with respect to operative time (WMD=17.98min, 95% CI: -2.18∼38.14, P = 0.08), blood loss (WMD=93.82ml, 95% CI: -32.68∼220.33, P = 0.15) and postoperative morbidity (OR = 0.88, 95% CI:0.57∼1.35, P = 0.55).
Conclusions
The present PSM and RCT data meta-analysis suggests that there does not appear to be a significant difference in survival between patients undergoing AR or NAR for HCC. Simultaneously, AR does not seem to bring more prognostic benefits in oncological outcomes including disease-free survival and overall survival. Considering unavoidable bias, more high-quality RCTs are badly needed to determine whether AR OR NAR can become standard practice for treating HCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai is responsible for the governance, coordination and running of the study.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract